SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-20-002547
Filing Date
2020-10-13
Accepted
2020-10-13 15:57:41
Documents
2
Period of Report
2020-10-13

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 11660
2 EX-16.1 nymox_ex161.htm EX-16.1 1440
  Complete submission text file 0001640334-20-002547.txt   14145
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 201236250
SIC: 2835 In Vitro & In Vivo Diagnostic Substances